Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 60/100

Notification of cessation of securities – RAD

Tuesday, February 25, 2025 1 min read
Key Takeaway: Radiopharm Theranostics has successfully dosed its first patient in a Phase 1/2a clinical study of BetaBart (RV-01). The company also announced that it received IND approval from the US FDA to initiate a therapeutic clinical study targeting B7H3. These developments mark significant progress for the company's clinical pipeline.
Price reaction · baseline $4.64 (2025-02-24 close) · hit pre-market · 2 other RADX headline(s) in the window, move may be shared
day 0 close
+5.2%
day 1
+6.3%
day 3 · peak
+7.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • Radiopharm Theranostics has initiated a Phase 1/2a clinical study.
  • The company received IND approval from the US FDA for Betabart (RV-01).

Full Press Release Details

• Announcements
• February 25, 2025
Loading Viewer…

More Announcements & Updates

• Announcements
• January 11, 2023
• RAD Articles
• October 21, 2024
• Announcements
• April 27, 2023
• Announcements
• June 27, 2024

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What is the BetaBart (RV-01) study about?

The BetaBart (RV-01) study is a Phase 1/2a clinical trial targeting B7H3.

Who approved the IND for Radiopharm's study?

The IND for the study was approved by the US FDA.

When was the first patient dosed in the study?

The first patient was dosed in the Phase 1/2a clinical study recently.

What is the significance of the FDA IND approval?

The FDA IND approval allows Radiopharm to initiate its therapeutic clinical study.

Tags: RADX Viatris Investor Conferences Healthcare Radiopharm Theranostics BetaBart Phase 1/2a FDA IND approval RV-01
Last updated: Feb 25, 2025